99 related articles for article (PubMed ID: 28914567)
1. Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.
Herting F; Friess T; Umaña P; Middleton S; Klein C
Leuk Lymphoma; 2018 Jun; 59(6):1482-1485. PubMed ID: 28914567
[No Abstract] [Full Text] [Related]
2. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
3. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
4. Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin.
Zhu D; Guo H; Chang Y; Ni Y; Li L; Zhang ZM; Hao P; Xu Y; Ding K; Li Z
Angew Chem Int Ed Engl; 2018 Jul; 57(30):9284-9289. PubMed ID: 29768700
[TBL] [Abstract][Full Text] [Related]
5. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Vernooij L; Bate-Eya LT; Alles LK; Lee JY; Koopmans B; Jonus HC; Schubert NA; Schild L; Lelieveld D; Egan DA; Kerstjens M; Stam RW; Koster J; Goldsmith KC; Molenaar JJ; Dolman MEM
Mol Cancer Ther; 2021 Jun; 20(6):1161-1172. PubMed ID: 33850004
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
O'Steen S; Green DJ; Gopal AK; Orozco JJ; Kenoyer AL; Lin Y; Wilbur DS; Hamlin DK; Fisher DR; Hylarides MD; Gooley TA; Waltman A; Till BG; Press OW
Cancer Res; 2017 Jul; 77(14):3885-3893. PubMed ID: 28566329
[TBL] [Abstract][Full Text] [Related]
7. Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Toutah K; Nawar N; Timonen S; Sorger H; Raouf YS; Bukhari S; von Jan J; Ianevski A; Gawel JM; Olaoye OO; Geletu M; Abdeldayem A; Israelian J; Radu TB; Sedighi A; Bhatti MN; Hassan MM; Manaswiyoungkul P; Shouksmith AE; Neubauer HA; de Araujo ED; Aittokallio T; Krämer OH; Moriggl R; Mustjoki S; Herling M; Gunning PT
J Med Chem; 2021 Jun; 64(12):8486-8509. PubMed ID: 34101461
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax active and safe in non-Hodgkin lymphoma.
Das M
Lancet Oncol; 2017 Mar; 18(3):e136. PubMed ID: 28139404
[No Abstract] [Full Text] [Related]
10. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
11. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.
Hicks SW; Lai KC; Gavrilescu LC; Yi Y; Sikka S; Shah P; Kelly ME; Lee J; Lanieri L; Ponte JF; Sloss CM; Romanelli A
Neoplasia; 2017 Sep; 19(9):661-671. PubMed ID: 28753442
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells.
Fujimura T; Yamashita-Kashima Y; Kawasaki N; Yoshiura S; Harada N; Yoshimura Y
Mol Cancer Ther; 2021 Jun; 20(6):1133-1141. PubMed ID: 33850006
[TBL] [Abstract][Full Text] [Related]
13. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
14. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
16. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax: First Global Approval.
Deeks ED
Drugs; 2016 Jun; 76(9):979-87. PubMed ID: 27260335
[TBL] [Abstract][Full Text] [Related]
18. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax-obinutuzumab: harnessing complexity.
Abrisqueta P; Bosch F
Blood; 2020 Mar; 135(11):788-789. PubMed ID: 32163557
[No Abstract] [Full Text] [Related]
20. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
